Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 20 March 2026 12:00 AM EOD	Asian-Paints2195.25	Hind-Unilever2083.90	ITC299.90	Trent3565.35	Larsen-and-Toubro3434.80	M-and-M3065.30	Reliance-Industries1414.55	Tata-Steel196.70	Titan-Company4108.20	SBI1058.40	Bharat-Electron426.05	Kotak-Mah-Bank366.95	Infosys1254.60	Bajaj-Finance830.40	Sun-PharmaInds1777.45	HDFC-Bank780.45	TCS2390.60	ICICI-Bank1245.55	Power-Grid-Corpn297.50	Maruti-Suzuki12602.65	Axis-Bank1204.25	HCL-Technologies1334.05	NTPC380.80	Bharti-Airtel1846.50	Tech-Mahindra1384.90	Adani-Ports1365.10	UltraTech-Cem10927.75	Bajaj-Finserv1709.75	Interglobe-Aviat4147.90	Eternal232.30
15 mins delay SENSEX 74,532.96 [325.72]	8.70 0.40%	6.45 0.31%	1.85 0.62%	83.75 2.41%	-0.45 -0.01%	19.70 0.65%	29.20 2.11%	6.15 3.23%	72.50 1.80%	9.45 0.90%	-4.75 -1.10%	-1.00 -0.27%	33.95 2.78%	-1.60 -0.19%	33.10 1.90%	-19.25 -2.41%	34.05 1.44%	-5.25 -0.42%	0.90 0.30%	11.20 0.09%	-2.40 -0.20%	22.70 1.73%	6.85 1.83%	17.35 0.95%	45.15 3.37%	9.30 0.69%	116.75 1.08%	-2.90 -0.17%	-9.30 -0.22%	3.40 1.49%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Zydus launches semaglutide injection under three brands in India

21-Mar-26 15:39Hrs IST

The company said the Drug Controller General of India (DCGI) had earlier approved the manufacturing and marketing of the Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.

Zydus stated that, unlike existing treatment options that require patients to purchase multiple single-dose pens during dose titration, it is offering a reusable multi-dose pen device. This innovation allows patients and clinicians to select and administer different dose strengths from a single pen, which the company claims will improve adherence, enhance convenience, and reduce overall treatment costs. The semaglutide injection will be available in a 15 mg/3 ml cartridge and will be manufactured at Zydus Biotech Park in Ahmedabad. The company said the average monthly cost of therapy is expected to be around Rs 2,200.

Zydus also highlighted that diabetes and obesity are major public health challenges in India. Citing the International Diabetes Federation, it noted that 8.9 crore adults in India are living with diabetes, representing 10.5% of the adult population. The company further pointed out a sharp rise in obesity prevalence among adults, increasing by 91% in women and 146% in men, underscoring the growing burden of lifestyle-related diseases in the country.

Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products.

The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences rose 1.63% to settle at Rs 890.60 on the BSE.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise